Anaïs Devey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anaïs Devey has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cécile Meex
Clinical Microbiology Laboratory, University Hospital of Liege, University of Liege, 4000 Liege, Belgium
2 shared publications - Pierrette Melin
Department of Clinical Microbiology, University Hospital of Liège, Liège, Belgium
2 shared publications Alex Frelik
Hospital Blood Transfusion Service and Donor Blood Center, CHU UCL Namur, Yvoir, Belgium; Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
1 shared publicationAndré Gothot
Immuno‐Hematology Laboratory and Blood Blank, Department of Clinical Biology University Hospital of Liège (B35) Liège Belgium
1 shared publicationCatherine Mbende
Hospital Blood Transfusion Service and Donor Blood Center, CHU UCL Namur, Yvoir, Belgium
1 shared publicationCécile Debry
Hospital Blood Transfusion Service and Donor Blood Center, CHU UCL Namur, Yvoir, Belgium; Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
1 shared publication
Latest Publications
- 23 June 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (10) , 1029-1038
Transfusion support and pre‐transfusion testing in autoimmune haemolytic anaemia
Autoimmune haemolytic anaemia (AIHA) is characterized by an increased destruction of red blood cells due to immune dysfunction and auto‐antibody production. Clinical manifestations are mainly related to anaemia, which can become life‐threatening in case of acute haemolysis. Aiming at counterbalancing severe anaemia, supportive treatments for these patients frequently include transfusions. Unfortunately, free serum auto‐antibodies greatly interfere in pre‐transfusion testing, and the identification of compatible red blood cell units for AIHA patients can be challenging or even impossible. Problems faced in pre‐transfusion testing often lead to delay or abandonment of transfusions for AIHA patients. In this review, we discuss publications concerning global transfusion management in AIHA, with a focus on pre‐transfusion testing, and practical clues to manage the selection of transfusion units for these patients. Depending on the degree of transfusion emergency, we propose an algorithm for the selection and laboratory testing of units to be transfused to AIHA patients.
- 23 June 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (10) , 1029-1038
Transfusion support and pre‐transfusion testing in autoimmune haemolytic anaemia
Autoimmune haemolytic anaemia (AIHA) is characterized by an increased destruction of red blood cells due to immune dysfunction and auto‐antibody production. Clinical manifestations are mainly related to anaemia, which can become life‐threatening in case of acute haemolysis. Aiming at counterbalancing severe anaemia, supportive treatments for these patients frequently include transfusions. Unfortunately, free serum auto‐antibodies greatly interfere in pre‐transfusion testing, and the identification of compatible red blood cell units for AIHA patients can be challenging or even impossible. Problems faced in pre‐transfusion testing often lead to delay or abandonment of transfusions for AIHA patients. In this review, we discuss publications concerning global transfusion management in AIHA, with a focus on pre‐transfusion testing, and practical clues to manage the selection of transfusion units for these patients. Depending on the degree of transfusion emergency, we propose an algorithm for the selection and laboratory testing of units to be transfused to AIHA patients.
- Open Access
- 17 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S278-S283
SLC14A1 gene sequencing shows the JK*01W.06 allele in a JK1 patient with an anti-JK1
- 17 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S278-S283
Open AccessSLC14A1 gene sequencing shows the JK*01W.06 allele in a JK1 patient with an anti-JK1
- 20 July 2023
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 27 (5) , 611-620
Multicenter Performance Evaluation of the Revogene® GBS DS Real-Time PCR Assay for Group B Streptococcus Detection During Labor
Purpose This study aimed to evaluate the performance and ease of use of the Revogene® GBS DS PCR assay for the intrapartum detection of Group B Streptococcus (GBS) colonization, as compared with intrapartum culture and antenatal culture-based screening. Methods Between April and August 2019, 398 women who gave birth in one of the three maternities participating in this study agreed to the collection of a vaginal swab when they arrived in the labor ward. The samples were immediately sent to the adjacent laboratory where they were discharged into the buffer provided with the Revogene® GBS DS assay. Part of the buffer was used to perform the Revogene® GBS DS test, and part of the same buffer was used for GBS culture. Results The Revogene® GBS DS assay provided a valid result in less than 70 min for 356 (89%) women. The sensitivity of the test was 85.7% (66.4–95.3%). The specificity of the test was 99.1% (97.3–99.8%). The positive predictive value was 88.9% (69.7–97.1%). The negative predictive value was 98.9% (96.9–99.6%). Conclusion The easy-to-use Revogene® GBS DS assay provides a valuable tool for the detection of GBS colonization at the beginning of labor. The sensitivity and turn-around time are adequate. The high number of invalid results needs to be addressed before the Revogene® GBS DS test can be expected to replace the current screening-based approach.
- 20 July 2023
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 27 (5) , 611-620
Multicenter Performance Evaluation of the Revogene® GBS DS Real-Time PCR Assay for Group B Streptococcus Detection During Labor
Purpose This study aimed to evaluate the performance and ease of use of the Revogene® GBS DS PCR assay for the intrapartum detection of Group B Streptococcus (GBS) colonization, as compared with intrapartum culture and antenatal culture-based screening. Methods Between April and August 2019, 398 women who gave birth in one of the three maternities participating in this study agreed to the collection of a vaginal swab when they arrived in the labor ward. The samples were immediately sent to the adjacent laboratory where they were discharged into the buffer provided with the Revogene® GBS DS assay. Part of the buffer was used to perform the Revogene® GBS DS test, and part of the same buffer was used for GBS culture. Results The Revogene® GBS DS assay provided a valid result in less than 70 min for 356 (89%) women. The sensitivity of the test was 85.7% (66.4–95.3%). The specificity of the test was 99.1% (97.3–99.8%). The positive predictive value was 88.9% (69.7–97.1%). The negative predictive value was 98.9% (96.9–99.6%). Conclusion The easy-to-use Revogene® GBS DS assay provides a valuable tool for the detection of GBS colonization at the beginning of labor. The sensitivity and turn-around time are adequate. The high number of invalid results needs to be addressed before the Revogene® GBS DS test can be expected to replace the current screening-based approach.
- 1 March 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (3) , 115616
Evaluation of the Revogene® GBS DS assay performance for the intrapartum screening of group B streptococcus in comparison with intrapartum culture
- 1 March 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (3) , 115616
Evaluation of the Revogene® GBS DS assay performance for the intrapartum screening of group B streptococcus in comparison with intrapartum culture